Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Atrium Research. This analysis is provided for institutional research purposes only and is not investment advice.
SOURCE UNAVAILABLE
Fund Returns
Annualized+1.7%
Positioning StanceNEUTRAL
Market CapSmallCap
GeographyUS
Digest Analysis
Quick Take
"Cannara Biotech delivered Q3 results ahead of estimates with revenue up 16% and EBITDA up 11%, maintaining strong margins while expanding market share in Ontario and Alberta. The company secured its first international supply deal with Curaleaf worth up to $21M and accelerated capacity expansion to 75,000kg by FY27."
Executive Summary
Atrium Research maintains a BUY rating and $3.00 target price on Cannara Biotech following Q3 2026 results that exceeded estimates with revenue of $31.8M (+16% YoY) and Adjusted EBITDA of $8.5M (+11% YoY). The company rebounded from seasonally soft Q2 performance while maintaining 42% gross margins above management's 40% target. National retail market share held at 4.4% with continued gains in Ontario (3.7% in June) and Alberta (2.9% in June), offsetting modest Quebec share decline. Cannara activated two additional grow zones and entered its first international supply agreement with Curaleaf worth up to $21M, accelerating capacity expansion by roughly one year to reach 75,000kg by end of FY27. The company ended the quarter with $21.8M in cash and $35.3M in debt. Atrium values LOVE at 10.0x FY26E Adjusted EBITDA, noting the stock trades at 6.5x FY26E EBITDA versus large-cap LPs at 6.0x-10.1x despite superior growth and margins. The analyst views the discount as unwarranted given the company's $250M purpose-built Valleyfield facility acquired for $33M, Quebec's lowest-in-Canada electricity costs, and clear path to $300M revenue at full 100,000kg capacity.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.